3-(2-aminoethyl)-1H-indol-6-ol - CAS 443-31-2
Catalog: |
BB054909 |
Product Name: |
3-(2-aminoethyl)-1H-indol-6-ol |
CAS: |
443-31-2 |
Synonyms: |
6-Hydroxytryptamine; 3-(2-aminoethyl)-1H-indol-6-ol; 3-(2-Amino-ethyl)-1H-indol-6-ol |
IUPAC Name: | 3-(2-aminoethyl)-1H-indol-6-ol |
Molecular Weight: | 176.21 |
Molecular Formula: | C10H12N2O |
Canonical SMILES: | C1=CC2=C(C=C1O)NC=C2CCN |
InChI: | InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-5-8(13)1-2-9(7)10/h1-2,5-6,12-13H,3-4,11H2 |
InChI Key: | WZTKTNRVJAMKAS-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2022047580-A1 | Hydroxylated psilocybin derivatives and methods of using | 20200901 |
TW-202132301-A | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | 20191113 |
TW-202132308-A | Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | 20191113 |
TW-202016072-A | Novel functionalized amides as modulators of 5-hydroxytryptamine receptor 7 and methods of use | 20180511 |
KR-20210020182-A | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 20180511 |
JP-2021523179-A | A novel functionalized lactam as a regulator of 5-hydroxytryptamine receptor 7 and how to use it | 20180511 |
WO-2019062662-A1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | 20170929 |
EP-3687989-A1 | Substituted pyrimidine piperazine compound and use thereof | 20170929 |
JP-2020535205-A | Substituted pyrimidine piperazine compounds and their use | 20170929 |
KR-20200022517-A | Fluoropiperidine Compounds as Pure 5-HT6 Receptor Antagonists | 20170807 |
PMID | Publication Date | Title | Journal |
21048351 | 20101101 | N-(3,5-dihydroxybenzoyl)-6-hydroxytryptamine as a novel human tyrosinase inhibitor that inactivates the enzyme in cooperation with l-3,4-dihydroxyphenylalanine | Chemical & pharmaceutical bulletin |
21358970 | 20100901 | Neurotoxins: free radical mechanisms and melatonin protection | Current neuropharmacology |
Complexity: | 174 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 176.094963011 |
Formal Charge: | 0 |
Heavy Atom Count: | 13 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 3 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 176.094963011 |
Rotatable Bond Count: | 2 |
Topological Polar Surface Area: | 62Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.2 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS